Enliven sticks to year-end ENABLE-2 start after FDA alignment on CML trial designNov 6Regulatory decisionEnliven TherapeuticsUpdated
Enliven Therapeutics adds Kristine Ball to board ahead of planned Phase 3 CML trialOct 14Clinical readoutEnliven Therapeutics
Enliven reports Phase 1 CML data for ELVN-001, aligns with FDA on Phase 3 designAug 5Quarterly updateEnliven Therapeutics